|
시장보고서
상품코드
1587794
림프종 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 약제별, 지역별, 부문별 예측(2025-2030년)Lymphoma Treatment Market Size, Share & Trends Analysis Report By Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
림프종 치료 시장 성장 및 동향:
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 림프종 치료 시장 규모는 2025년부터 2030년까지 연평균 8.3%의 CAGR을 기록하여 2030년에는 119억 7,000만 달러에 달할 것으로 예상됩니다.
새로운 치료제 개발을 위한 연구 활동의 활성화와 제품 라인업의 확대가 성장을 촉진할 가능성이 높습니다. 신약 상용화의 증가는 성장을 더욱 촉진할 것으로 예상됩니다.
다양한 제품의 가용성은 성장을 더욱 촉진할 것으로 예상됩니다. 예를 들어, 2019년 1월, 베이진은 미국 FDA로부터 성인 맨틀세포 림프종 치료인 자누브루티닙(Zanubrutinib)에 대해 획기적 치료제 지정을 받았습니다. 이 약물은 현재 후기 임상시험 중이며 예측 기간 내에 출시될 것으로 예상됩니다.
의료진과 환자들 사이에서 림프종 조기 진단에 대한 인식이 높아지고 있으며, 연구개발에 대한 정부의 자금 지원이 증가하고 있는 것은 시장 성장을 촉진할 것으로 예상되는 몇 가지 요인입니다. 예를 들어, 미국 국립암연구소(National Cancer Institute)와 같은 연구 기관은 미국 의회로부터 암 관련 연구 및 관련 활동을 지원하기 위해 자금을 지원받고 있습니다.
림프종 치료 시장 보고서 하이라이트
- 비호지킨림프종(NHL)이 2024년 86.2%의 최대 매출 점유율로 시장을 장악했으며, NHL 발병률 증가에 따라 향후 몇 년 동안 환자 수가 크게 증가할 것으로 예상됩니다.
- 호지킨림프종(HL)은 진단 건수 증가와 조기 발견을 촉진하는 진단 기술 발전으로 인해 예측 기간 동안 연평균 15.7%의 성장률을 보일 것으로 예상됩니다.
- 리툭산(성분명: 맙셀라)이 2024년 28.8%의 최대 매출 점유율을 차지하며 시장을 장악했습니다. 이는 비호지킨림프종(NHL)을 중심으로 다양한 적응증에 광범위하게 사용되면서 효능이 입증되었기 때문입니다.
- 키티루다는 특히 진행성 또는 난치성 질환에 대한 주요 면역치료제로서 예측 기간 동안 18.9%의 CAGR로 가장 빠른 성장을 보일 것으로 예상됩니다.
- 병원 약국은 2024년 36.1%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
- 북미의 림프종 치료 시장은 2024년 49.0%의 최대 매출 점유율로 세계 시장을 석권했는데, 이는 림프종 사례, 특히 비호지킨 림프종의 높은 유병률에 기인한 것으로 분석됩니다.
- 아시아태평양의 림프종 치료 시장은 유병률 증가와 의료비 지출 증가로 인해 빠르게 성장할 것으로 예상됩니다. 이 지역 국가들은 의료 인프라가 개선되고 혁신적인 치료법에 대한 접근성이 향상되고 있습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 림프종 치료 시장 변수, 동향, 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비즈니스 환경 분석
- 업계 분석 - Porter's Five Forces 분석
- PESTLE 분석
제4장 림프종 치료 시장 : 약제 추정·동향 분석
- 부문 대시보드
- 림프종 치료 시장 : 약제 변동 분석, 2024년 및 2030년
- 호지킨림프종
- 비호지킨림프종
제5장 림프종 치료 시장 : 약제 추정·동향 분석
- 부문 대시보드
- 림프종 치료 시장 : 약제 변동 분석, 2024년 및 2030년
- Rituxan/MabThera
- Revlimid
- Imbruvica
- Adcetris
- Keytruda
- Opdivo
- 기타
제6장 림프종 치료 시장 : 유통 채널 추정·동향 분석
- 부문 대시보드
- 림프종 치료 시장 : 유통 채널 변동 분석, 2024년 및 2030년
- 병원 약국
- 소매 약국
- 전문 약국
- 기타
제7장 림프종 치료 시장 : 지역 추정·동향 분석
- 지역별 시장 점유율 분석, 2024년 및 2030년
- 지역 시장 대시보드
- 시장 규모, 예측 동향 분석, 2018-2030년 :
- 북미
- 미국
- 캐나다
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 아랍에미리트
제8장 경쟁 상황
- 주요 시장 진출 기업의 최근 동향과 영향 분석
- 기업 분류
- 기업 히트맵 분석
- 기업 개요
- Bristol-Myers Squibb Company
- Celgene Corporation
- Merck &Co., Inc.
- F. Hoffmann-La Roche Ltd
- Seattle Genetics, Inc.
- Takeda Pharmaceutical Company Ltd
- Johnson & Johnson
- Eli Lilly and Company
- AstraZeneca
- Novartis AG
Lymphoma Treatment Market Growth & Trends:
The global lymphoma treatment market size is expected to reach USD 11.97 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.
Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.
Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.
Lymphoma Treatment Market Report Highlights:
- Non-Hodgkin Lymphoma (NHL) dominated the market with the largest revenue share of 86.2% in 2024, driven by the increasing incidence of NHL, with projections indicating a significant rise in cases over the coming years.
- Hodgkin Lymphoma (HL) is expected to grow at a CAGR of 15.7% over the forecast period attributed to a rising number of diagnosed cases and advancements in diagnostic technologies that facilitate earlier detection.
- Rituxan (MabThera) dominated the market and accounted for the largest revenue share of 28.8% in 2024, attributed to its established efficacy and broad usage across various indications, particularly non-Hodgkin lymphoma (NHL).
- Keytruda is expected to grow at the fastest CAGR of 18.9% over the forecast period, owing to its status as a leading immunotherapy option, particularly for advanced or refractory cases.
- Hospital pharmacies dominated the market and accounted for the largest revenue share of 36.1% in 2024 attributed to the increasing prevalence of lymphoma cases requiring specialized care.
- The lymphoma treatment market in North America dominated the global market and accounted for the largest revenue share of 49.0% in 2024, owing to the high prevalence of lymphoma cases, particularly non-Hodgkin lymphoma, which accounts for a significant portion of cancer diagnoses.
- The Asia Pacific lymphoma treatment market is projected to grow rapidly due to rising incidence rates and increasing healthcare spending. Countries in this region are experiencing improvements in healthcare infrastructure and access to innovative treatments
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Drug
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Lymphoma Treatment Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Lymphoma Treatment Market: Drug Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
- 4.3. Hodgkin Lymphoma
- 4.3.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Non-Hodgkin Lymphoma
- 4.4.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Lymphoma Treatment Market: Drug Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
- 5.3. Rituxan/MabThera
- 5.3.1. Rituxan/MabThera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Revlimid
- 5.4.1. Revlimid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Imbruvica
- 5.5.1. Imbruvica Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Adcetris
- 5.6.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Keytruda
- 5.7.1. Keytruda Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8. Opdivo
- 5.8.1. Opdivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.9. Others
- 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Lymphoma Treatment Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Lymphoma Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
- 6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Retail Pharmacy
- 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Specialty Pharmacy
- 6.5.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Lymphoma Treatment Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework
- 7.4.2.3. Competitive Insights
- 7.4.2.4. U.S. Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework
- 7.4.3.3. Competitive Insights
- 7.4.3.4. Canada Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework
- 7.5.2.3. Competitive Insights
- 7.5.2.4. UK Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework
- 7.5.3.3. Competitive Insights
- 7.5.3.4. Germany Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework
- 7.5.4.3. Competitive Insights
- 7.5.4.4. France Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework
- 7.5.5.3. Competitive Insights
- 7.5.5.4. Italy Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework
- 7.5.6.3. Competitive Insights
- 7.5.6.4. Spain Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework
- 7.6.2.3. Competitive Insights
- 7.6.2.4. Japan Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework
- 7.6.3.3. Competitive Insights
- 7.6.3.4. China Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework
- 7.6.4.3. Competitive Insights
- 7.6.4.4. India Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework
- 7.6.5.3. Competitive Insights
- 7.6.5.4. South Korea Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework
- 7.6.6.3. Competitive Insights
- 7.6.6.4. Australia Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework
- 7.7.2.3. Competitive Insights
- 7.7.2.4. Brazil Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory Framework
- 7.7.3.3. Competitive Insights
- 7.7.3.4. Argentina Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework
- 7.8.2.3. Competitive Insights
- 7.8.2.4. South Africa Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework
- 7.8.3.3. Competitive Insights
- 7.8.3.4. UAE Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Bristol-Myers Squibb Company
- 8.4.1.1. Overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Celgene Corporation
- 8.4.2.1. Overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Merck & Co., Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. F. Hoffmann-La Roche Ltd
- 8.4.4.1. Overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Seattle Genetics, Inc.
- 8.4.5.1. Overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Takeda Pharmaceutical Company Ltd
- 8.4.6.1. Overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Johnson & Johnson
- 8.4.7.1. Overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Eli Lilly and Company
- 8.4.8.1. Overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. AstraZeneca
- 8.4.9.1. Overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Novartis AG
- 8.4.10.1. Overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives
- 8.4.1. Bristol-Myers Squibb Company
